O12.4. EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE ON BONE STATUS IN OBESE, NON-DIABETIC, ANTIPSYCHOTIC-TREATED SCHIZOPHRENIA SPECTRUM PATIENTS

BACKGROUND: Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect bone turnover. The current study comprises p...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Schizophr Bull
Päätekijät: Eriksson, Robert, Broberg, Brian V, Ishoy, Pelle Lau, Bak, Nikolaj, Andersen, Ulrik B, Jørgensen, Niklas R, Knop, Filip K, Ebdrup, Bjorn
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2019
Aiheet:
Oral Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6455238/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbz021.268
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia